Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

NCT Number	NCT06175000
Lead Sponsor	Providence Health & Services
Conditions	Primary Central Nervous System Lymphoma
Enrollment	28 participants
Start Date	2024-03-13
Primary Completion	2028-09-15 (estimated)
Study Completion	2029-09-15 (estimated)
Updated on ClinicalTrials.gov	2025-06-05